The invention discloses a recombinant protein (P-selectin glycoprotein ligand-1 and Neural Retina-specific Leucine Zipper) PSGL-1-NRL chimeric protein comprising a Selectin Binding domain and a non-covalent dimerization domain, which is a leucine zipper and is more preferably the leucine zipper domain of the human or mouse Neural Retina-specific Leucine Zipper. The chimeric protein further comprises a covalent dimerization domain with at least one cysteine suitable to form a disulfide bridge with another chimeric protein to form a homodimer. In the chimeric protein, the PSGL-1 domain corresponds to the extracellular region of Human PSGL-1 and is more preferably the selectin binding region of the mature protein. The chimeric protein is correctly post-translationally modified and is efficiently expressed in a mammalian system. It is sulfated, O-linked glycosylated and sialylated and binds P, E and L selectin, allowing in vivo and in vitro targeting for diagnostic or therapeutic purposes.

An apparatus can be used to generate acoustic imaging pulse sequences and receive corresponding echoes elicited by the acoustic imaging pulse sequences. An acoustic radiation force (ARF) pulse sequence can be generated to agitate a contrast medium in a tissue region between the acoustic imaging pulse sequences. A decorrelation between images corresponding to the received echoes can be determined. A weighting map can be applied to an image to weight a region of the image corresponding to a spatial location of the contrast medium using the determined decorrelation. In an example, the receiving of corresponding echoes elicited by the acoustic imaging pulse sequences can include receiving acoustic energy having a range of frequencies offset from a fundamental frequency associated with the acoustic imaging pulse sequences. An acoustic imaging pulse sequence can include a pulse having an inverted amplitude envelope with respect to another pulse included in the sequence.

A method of non-invasively detecting and purging bacterial cells using a modified photoacoustic in vivo flow cytometer device is described herein. In particular, a method of detecting bacterial cells by analyzing photoacoustic pulses emitted in response to laser pulses from a pulsed laser source and/or selectively destroying the detected bacterial cells using a non-linear photothermal response induced by a high-energy laser pulse is described herein.

A method for ascertaining the presence of target-bound microbubbles in the context of ultrasound molecular imaging is taught. This method, referred to herein as dynamic scaling ultrasound molecular imaging, relies upon the time-varying behavior contrast agents within a region expressing a molecular imaging target and that within a reference region. Ultrasound contrast agent compositions that enable use of the method are also taught. The invention is useful for the use of ultrasound molecular imaging in diagnosing disease and monitoring treatment.

The presently disclosed subject matter provides compositions, kits, and methods comprising imaging agents that can detect Programmed Cell Death Ligand 1 (PD-L1). The presently disclosed imaging agents can be used to detect diseases and disorders, such as cancer, infection, and inflammation, in a subject.

The present subject matter provides compounds, compositions, and methods for identifying, monitoring, treating, and removing diseased tissue. Compounds, compositions, and methods for identifying, monitoring, and detecting circulating fluids such as blood are also provided.

A method of non-invasively detecting and purging bacterial cells using a modified photoacoustic in vivo flow cytometer device is described herein. In particular, a method of detecting bacterial cells by analyzing photoacoustic pulses emitted in response to laser pulses from a pulsed laser source and/or selectively destroying the detected bacterial cells using a non-linear photothermal response induced by a high-energy laser pulse is described herein.

The invention described herein relates to colloidal particles useful for photoacoustic imaging. The particles comprise a photoacoustic imaging agent with an absorbance maximum or plateau in the range of wavelengths 700-1100 nm. The imaging agent also displays low optical absorbance at some wavelength in the range 700-1100 nm. This combination of high and low optical absorbance enables background subtraction in photoacoustic imaging applications. The imaging agent is an organic compound having low aqueous solubility so that it is stably encapsulated in the hydrophobic core of the particle. The particle is stabilized by a polymeric surface coating, and the polymeric stabilizing layer on the surface of the particle may contain targeting ligands for targeted diagnostics or therapeutic delivery. The particle core may also contain therapeutic agents or other imaging agents.

The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.

A method for ascertaining the presence of target-bound microbubbles in the context of ultrasound molecular imaging is taught. This method, referred to herein as dynamic scaling ultrasound molecular imaging, relies upon the time-varying behavior contrast agents within a region expressing a molecular imaging target and that within a reference region. Ultrasound contrast agents compositions that enable use of the method are also taught. The method is useful for the use of ultrasound molecular imaging in diagnosing and monitoring treatment.